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Abstract
Background: Many chemotherapeutic agents have been used to treat pancreatic cancer without
success. Apigenin, a naturally occurring flavonoid, has been shown to inhibit growth in some cancer
cell lines but has not been studied in pancreatic cancer. We hypothesized that apigenin would
inhibit pancreatic cancer cell growth in vitro.
Results: Apigenin caused both time- and concentration-dependent inhibition of DNA synthesis
and cell proliferation in four pancreatic cancer cell lines. Apigenin induced G2/M phase cell cycle
arrest. Apigenin reduced levels of cyclin A, cyclin B, phosphorylated forms of cdc2 and cdc25, which
are all proteins required for G2/M transition.
Conclusion: Apigenin inhibits growth of pancreatic cancer cells through suppression of cyclin B-
associated cdc2 activity and G2/M arrest, and may be a valuable drug for the treatment or
prevention of pancreatic cancer.
Background
Despite attempts of resection and adjuvant therapy,
patients diagnosed with pancreatic cancer continue to
have a poor prognosis. Many chemotherapeutic agents
have been used to treat pancreatic cancer without particu-
lar success. Novel treatments to inhibit cancer cell prolif-
eration with less toxicity are needed. Flavonoids are a class
of polyphenolic compounds which display a variety of
biologic activities. There has been recent interest in using
flavonoid derivatives therapeutically as anticancer drugs.
At pharmacological levels, various naturally occurring fla-
vonoids have been shown to be cancer-protective in a
variety of animal models. Flavonoid derivatives, such as
flavopiridol and genistein, have been shown to be safe in
human trials[1,2] and are being assessed as chemotherapy
drugs in phase II clinical trials for advanced solid tumors
[3,4].
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Flavonoids have shown antitumor activity for a number
of cancer cell types [5,6]. This is mediated by different
types of cell cycle arrest and the induction of apoptosis in
several tumor cell lines [7-12]. Genistein, a naturally
occurring isoflavone, has shown antitumor activity in
pancreatic cancer models [13]. Apigenin, an isoconformer
of genistein, has shown more potent growth inhibition in
several cancer cell lines [6]. Apigenin has been shown to
possess anti-inflammatory effects, free radical scavenging
properties, and anti-carcinogenic effects [14]. It has been
shown to possess growth inhibitory properties in several
cancer lines, including breast, colon, skin, thyroid, and
leukemia cells [15-19], but has never been studied in pan-
creatic cancer. We hypothesized that apigenin would
inhibit pancreatic cancer cell growth in vitro, and further
aimed to delineate the mechanism involved.
Results
Apigenin inhibited DNA synthesis
Apigenin caused a concentration-dependent (6.25–100
μM) inhibition of thymidine incorporation in all four cell
lines studied (Figure 1). At 24 hours, 100 μM apigenin
caused an approximately 50% inhibition of thymidine
incorporation in each cell line. The inhibition of prolifer-
ation was statistically significant (P < 0.01) at 100 μM api-
genin in all cell lines.
Effects of apigenin on DNA synthesis in human pancreatic cancer cells Figure 1
Effects of apigenin on DNA synthesis in human pancreatic cancer cells. Apigenin caused significant concentration-
dependent inhibition of DNA synthesis in all four cell lines studied: AsPC-1 [F (5,42) = 10.12, P < 0.0001; P = 0.01 with 50–100 
μM]; CD18 [F (5,54) = 38.47, P < 0.0001; P < 0.01 with 12.5–100 μM]; MIA PaCa2 [F (5,72) = 8.698, P < 0.0001; P < 0.05 with 
25 μM and P < 0.01 with 50–100 μM]; S2-013 [F (5,72) = 4.099, P < 0.0025; P < 0.05 with 50 μM and P < 0.01 with 100 μM]. 
Data represent results from at least three separate experiments each performed in triplicate, expressed as a percentage of 
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Apigenin inhibited cell proliferation
The inhibition of DNA synthesis correlated with a
decrease in cell number over a 72-hour period when com-
pared with control. The cell number in untreated cells
increased every 24 hours in almost every cell line while
cell number of apigenin-treated cells increased at a slower
rate, or decreased (Figure 2). The differences in cell
number were statistically significant (P < 0.05) at 72 hours
in all four cell lines. During the first 24 hours, no signifi-
cant difference was seen between cells treated with api-
genin and controls. Only viable cells were counted so that
cytotoxicity did not play a role.
Apigenin induced G2/M phase cell cycle arrest
In order to better understand the mechanism of inhibi-
tion of cell proliferation, the distribution of cells in the
different phases of the cell cycle was analyzed following
treatment with 100 μM apigenin for 24 hours. There were
marked and consistent changes in the cell cycle at 24
hours. The number of cells in the G2/M phase increased
in all four cell lines with a concomitant decrease in treated
cells in the G0/G1 and S phase. The difference between
the mean percentage of control and treated cells in the
G2/M phase of four separate experiments was statistically
significant in all four cell lines (AsPC1: P < 0.01, CD18: P
< 0.009, MiaPaCa2: P < 0.04; S2013: P < 0.03). Figure 3
shows the results of one experiment representative of all
cell cycle experiments. The concentration-dependent
Time-course effects of apigenin on cell number of human pancreatic cells Figure 2
Time-course effects of apigenin on cell number of human pancreatic cells. Apigenin significantly inhibited the 
increase in cell number of each cell line over time: AsPC-1, [F (5,59) = 10.65, P < 0.0001], P < 0.05 at 48 h and P < 0.001 at 72 
h; CD18, [F (5,38) = 5.641, P < 0.0006], P < 0.001 at 72 h; MIA PaCa2, [F (5,65) = 6.127, P < 0.0001], P < 0.001 at 72 h; S2-013, 
[F (5,60) = 2.589, P < 0.0347], P < 0.05 at 72 h. Data represent results from at least three separate experiments each per-
formed in triplicate, expressed as cell number/well. *= P < 0.05; **= P < 0.01; ***= P < 0.001 compared with control.Molecular Cancer 2006, 5:76 http://www.molecular-cancer.com/content/5/1/76
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effects of apigenin on the proportion of cells in the G2/M
phase of the cell cycle are shown in Figure 4.
Apigenin changed expression of proteins involved in the 
G2/M phase transition
All four pancreatic cancer cell lines were treated with 100
μM apigenin for 24 hours and expression and phosphor-
ylation of proteins involved in the G2/M transition were
observed through western blotting (Figure 5). Expression
of cyclin A and B was decreased in apigenin treated cells
when compared to controls. While expression of cdc2 was
unchanged, the levels of phosphorylated cdc2 were
decreased in apigenin treated cells. Expression of cdc25A
and cdc25C were also decreased in apigenin treated cells
compared to controls.
Discussion
Several mechanisms have been proposed for apigenin's
effect on cell growth including modulation of the MAP
kinase pathway [20,21], inhibition of ornithine decarbox-
ylase [22], improvement in cell-cell communication
through increased gap junctions [23], and cell cycle arrest.
Cell-cycle checkpoints at G2/M as well as G1/S are critical
in maintaining DNA integrity and regulating the passage
of cells through the cell cycle. It is well known that loss of
these checkpoints is involved in the transformation into
and progression of cancer cells. A protein kinase complex
consisting of a catalytic subunit, cdc2, and the cyclin B
protein performs the central and rate-limiting function in
the transition from G2 to M phase [24]. The cdc2/cyclin B
complex responds to DNA damage and causes a delay in
cell cycle progression to allow DNA repair before cells
Effects of apigenin on the proportion of cells in different phases of the cell cycle Figure 3
Effects of apigenin on the proportion of cells in different phases of the cell cycle. Apigenin caused G2/M arrest in all 
four human pancreatic cancer cell lines studied. Similar results were seen in four different experiments.Molecular Cancer 2006, 5:76 http://www.molecular-cancer.com/content/5/1/76
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enter mitosis. The complex accomplishes this through
phosphorylation of cytoskeleton proteins such as lamins
and histone H1 [25]. Cdc2 binding to cyclin B in and of
itself is not enough, however, for checkpoint progression.
Dephosphorylation of cdc2 at the Tyr-15 site through
cdc25c phosphatase is required for activation of the com-
plex [24,26]. Cdc25A also contributes to the cellular phos-
phatase pool required to dephosphorylate cdc2 fully [27].
Cyclin A, known mainly for its role in G1/S transition, is
also required for the entry of cells into mitosis [28,29].
In the current study, treatment of human pancreatic can-
cer cells with apigenin resulted in inhibition of DNA syn-
thesis and cell proliferation through G2/M cell cycle
arrest. A decrease in levels of cyclin A, cyclin B, cdc25 A
and cdc25C all appear to be involved. It is not clear why
levels of phosphorylated cdc2 were decreased given that
reduced levels of cdc25c should have the opposite effect,
however, the reduced levels of cyclin B appear to be the
main mechanism involved in the arrest of cells at G2/M.
Our results are congruent with previous studies in which
cell cycle arrest has been shown to result from apigenin
treatment in other cell lines. G2/M arrest through inhibi-
tion of cyclin B associated cdc2 has been shown to occur
in epidermal and fibroblast cells [8,30], breast cancer cells
[31], oral cancer cells [32], melanoma [33], mouse kerat-
inocytes [34], endothelial cells [35], prostate cancer cells
[36], and colon cancer cell lines [16]. Interestingly, inhibi-
tion of cyclin B appears to be concentration-related as
lower doses have less effect while higher doses (>70 μM)
as we used in our study decrease cyclin B levels [34].
Concentration-dependent effects of apigenin on the cell cycle Figure 4
Concentration-dependent effects of apigenin on the cell cycle. Higher concentrations of apigenin cause a concomitant 
increase in the percentage of cells in the G2/M phase. AsPC-1 [F (3,8) = 12.79, P < 0.002 (P < 0.01 with 100 μM)]; CD18 [F 
(3,8) = 9.504, P < 0.0128 (P < 0.05 with 50 μM and P < 0.01 with 100 μM)]; MIA PaCa2 [F (3,10) = 6.062, P < 0.0128(P < 0.01 
with 100 μM)]; S2-013 [F (3,10) = 4.071, P < 0.0394 (P < 0.05 with 100 μM)]. *= P < 0.05; **= P < 0.01 compared with control.Molecular Cancer 2006, 5:76 http://www.molecular-cancer.com/content/5/1/76
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A considerable amount of attention has been given to the
role of p53 in cell cycle checkpoint control. P53 blocks
cells at G2/M through direct inhibition of cdc2 kinase
[37]. All four cell lines used in this study contain mutated
p53, which implies that the G2/M arrest seen after api-
genin treatment is through a p53-independent pathway.
Other studies have found this to be the case as well. Api-
genin was found to inhibit growth in both p53 wild-type
and mutated breast cancer cells [15], p53 mutated oral
squamous cell cancer cells [32], and mutated colon cancer
cell lines [16].
Conclusion
To our knowledge there is no published data concerning
apigenin in pancreatic cancer. Our results demonstrate
that apigenin inhibits human pancreatic cancer cell
growth in vitro through G2/M phase cell cycle arrest asso-
ciated with decreased cyclin B-cdc2 activity. Taken
together with previously published studies, apigenin
appears to exert its inhibitory effects on cell cycle progres-
sion in other cell lines as well. Cancer cells with abnormal
cell-cycle machinery may benefit from extrinsic cell-cycle
regulators such as apigenin.
Methods
Materials
DMEM, trypsin-EDTA solution, and propidium iodide
were purchased from Sigma (St. Louis, MO). Fetal bovine
serum was purchased from Atlanta Biologicals (Norcross,
GA). Apigenin was purchased from Calbiochem (Darm-
stadt, Germany) and dissolved in DMSO purchased from
Sigma Chemicals (St. Louis, MO). Methyl 3H-Thymidine
was purchased from Amersham (Arlington Heights, IL).
The monoclonal mouse cyclin A, B, cdc25A, and GAPDH
antibodies, and the polyclonal rabbit cdc25C antibody
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). The monoclonal rabbit cdc2 and phospho-
cdc2 (Tyr15) antibodies were purchased from Cell Signal-
ing Technology, Inc. (Beverly, MA).
Human pancreatic cancer cell lines and cell culture
We selected four human pancreatic cancer cell lines:
AsPC-1, CD18, MIA PaCa2, and S2-013. These cell lines
were purchased from American Type Culture Collection
(Manassas, VA) with the exception of the S2-013 cell line,
which was a generous gift from Dr. Takeshi Iwamura
(Japan). Each cell line was grown in DMEM and plated as
Effects of apigenin on proteins involved in the G2/M cell cycle phase transition Figure 5
Effects of apigenin on proteins involved in the G2/M cell cycle phase transition. Expression of both cyclin A and cyc-
lin B were both decreased in apigenin-treated cells compared to controls. While the expression of the cdc2 protein was 
unchanged, levels of phosphorylated cdc2 were decreased in treated cells. Expression of cdc25A and cdc25C were also 
decreased in treated cells compared to controls.Molecular Cancer 2006, 5:76 http://www.molecular-cancer.com/content/5/1/76
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monolayers in medium supplemented with 10% fetal
bovine serum in a humidified atmosphere of 95% O2 and
5% CO2 at 37°C. The cells were regularly seeded into 75-
cm2 flasks with media changes every second or third day.
For experiments, cells were grown to 70% confluence,
digested with trypsin-EDTA, and plated in 6-, 24-, or 48-
well plates.
DNA synthesis by methyl-3H thymidine incorporation
Cells were plated in 24-well plates at a concentration of
50,000 cells/well. After reaching 50% confluence, they
were incubated in serum-free medium for 24 hours,
which was then replaced with fresh serum-free medium
with or without the appropriate treatments. After the
required period of culture, cellular DNA synthesis was
assayed by adding 0.5μCi methyl 3H-thymidine/well and
incubating cells for another 6 hours. The cells were then
washed twice with PBS, fixed with 10% trichloroacetic
acid, and solubilized by adding 250 μl of 0.4 M NaOH to
each well. Radioactivity, indicating incorporation of
methyl 3H-thymidine into DNA, was measured by adding
scintillation cocktail and counting on a scintillation coun-
ter (LKB RackBeta; Wallac, Turku, Finland).
Cell proliferation assay
Cells were regularly seeded into three 6-well plates and
incubated at 37°C for 24 hours. Cells were then cultured
in serum-free medium for another 24 hours and treated in
fresh serum-free medium with or without apigenin for 24,
48, and 72 hours. At the end of each time period, the cells
were trypsinized to produce a single cell suspension, and
the viable cell number in each well was counted using
Guava Technologies' ViaCount Assay (Guava Technolo-
gies Inc, Hayward, CA).
Analysis of cellular DNA content by flow cytometry
Cells were grown to 50% confluence in T75-cm2 flasks,
serum starved for 24 hours, and then treated with api-
genin. At the end of the treatment, the cells were harvested
with trypsin-EDTA solution to produce a single-cell sus-
pension. Cells were then pelleted by centrifugation and
washed twice with PBS. The cell pellets were then sus-
pended in 0.5 mL PBS and fixed in ice-cold 70% ethanol
at 4°C. The fixed cells were then centrifuged at ×300 g for
10 minutes and pellets washed with PBS. After resuspen-
sion in 1 ml PBS, the cells were incubated with 10 μL
Rnase I (10 mg/ml) and 100 μL propidium iodide (400 g/
mL) and shaken for 1 hour at 37°C in the dark. The sam-
ples were then analyzed by flow cytometry.
Western blotting
Cells were seeded in T25-cm2 flasks and grown to 60%
confluence for 24 hours. The cells were serum starved for
24 hours. The cells were then placed in serum-free
medium with or without 100 μM apigenin for 24 hours.
The cells were lysed and protein concentrations deter-
mined with BSA as standard. Equal amounts of cell pro-
tein lysate were separated on 15% SDS-polyacrylamide gel
electrophoresis (PAGE) and the protein transferred onto
nitrocellulose membranes. After blocking with dried milk,
membranes were incubated with the appropriate dilution
of primary antibody. Membranes were then incubated
with a horseradish peroxidase-conjugated secondary anti-
body. Proteins were detected using the enhanced chemilu-
minescence detection system.
Statistical analysis
Data were analyzed by ANOVA with Dunnett's or Bon-
feroni's corrections for multiple comparisons, as appro-
priate. This analysis was performed with the Prism
software package (GraphPad, San Diego, CA). Data were
expressed as mean ± SEM.
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